BRAF and melanoma: Nonetheless, we have observed improvement in RFS after adjuvant therapy, especially in the BRAF/MEK-inhibitor-treated group, which is consistent with data from clinical trials demonstrating that, in BRAF-mutated stage III patients, the impact of adjuvant therapy with BRAF/MEK for preventing melanoma relapses is higher during the first year of active therapy than in patients treated with immunotherapy.